Literature DB >> 2845083

9-Benzyl-6-(dimethylamino)-9H-purines with antirhinovirus activity.

J L Kelley1, J A Linn, M P Krochmal, J W Selway.   

Abstract

A series of 9-benzyl-6-(dimethylamino)-9H-purines and 9-benzyl-2-chloro-6-(dimethylamino)-9H-purines were synthesized and tested in cell culture for activity against rhinovirus type 1B. The 9-benzylpurines that were unsubstituted in the 2-position had weak activity. However, introduction of a 2-chloro substituent resulted in a substantial increase in antiviral activity. One of the most active compounds, 2-chloro-6-(dimethylamino)-9-(4-methylbenzyl)-9H-purine (29), had an IC50 value of 0.08 microM against serotype 1B. Four compounds were tested against 18 other rhinovirus serotypes, but the majority tested were less sensitive than type 1B. The range of serotype sensitivity for 29 varied from 0.08 to 14 microM. These 9-benzyl-2-chloro-9H-purines represent a new class of antiviral agents with in vitro activity against rhinoviruses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845083     DOI: 10.1021/jm00118a025

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.

Authors:  Wen-Lian Wu; Jinsong Hao; Martin Domalski; Duane A Burnett; Dmitri Pissarnitski; Zhiqiang Zhao; Andrew Stamford; Giovanna Scapin; Ying-Duo Gao; Aileen Soriano; Terri M Kelly; Zuliang Yao; Mary Ann Powles; Shiying Chen; Hong Mei; Joyce Hwa
Journal:  ACS Med Chem Lett       Date:  2016-03-12       Impact factor: 4.345

2.  A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.

Authors:  Barry C Johnson; Gary T Pauly; Ganesha Rai; Disha Patel; Joseph D Bauman; Heather L Baker; Kalyan Das; Joel P Schneider; David J Maloney; Eddy Arnold; Craig J Thomas; Stephen H Hughes
Journal:  Retrovirology       Date:  2012-12-05       Impact factor: 4.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.